Pioglitazone

Mechanism of Action

Pioglitazone binds to and activates the nuclear receptor peroxisome proliferator-activated receptor 𝛄 (PPAR𝛄) found primarily in the nucleus of adipocytes, but also in muscle fibres and hepatocytes. 

Activation leads to heterodimerisation with retinoid X receptors (RXR). This complex interacts with DNA via binding to peroxisome proliferator response elements (PPREs) to promote gene transcription for multiple genes involved in glucose and lipid metabolism.

The resulting changes in gene expression have shown to cause an increased insulin sensitivity of liver, fat and skeletal muscle cells; meaning the body responds better to the insulin produced. This leads to reduced hepatic gluconeogenesis (glucose production). Pioglitazone has shown to reduce requirements for exogenous insulin by around 30% to maintain blood glucose. 

Pioglitazone requires endogenous insulin to elicit its pharmacological effect and is therefore not effective in the treatment of type 1 diabetes. There is a relatively low risk of hypoglycaemia when pioglitazone is used as monotherapy, however the risk is increased if used in combination with other hypoglycaemia inducing agents (such as sulfonylureas and insulin).

Upregulated Proteins

Pioglitazone leads to increased expression of the following proteins:

Glucose Transporter Type 4 (GLUT-4)

• Glucose enters adipocytes and skeletal muscle cells via the GLUT-4 transporter, upregulation leads to a reduction in plasma glucose levels

Fatty Acid Transporter Proteins (FATP)

• FATP promote free fatty acids uptake and storage in adipose tissue and distribution away from tissues such as skeletal muscle and the liver, which can increase insulin sensitivity. 

Lipoprotein Lipase (LPL)

• LPL leads to cleavage of triglycerides in plasma leading to release of free fatty acids, which are taken into the adipocyte. This leads to a reduction in circulating triglycerides.

Movement of free fatty acids into adipocytes is associated with reduced insulin resistance. Pioglitazone has also been shown to increase high density lipoprotein (HDL) cholesterol.

Created in BioRender. Boucher, M. (2026) https://BioRender.com/jt4vce5

Fig 1
Mechanism of Action of pioglitazone. Pioglitazone binds to and activates the nuclear receptor peroxisome proliferator-activated receptor 𝛄 (PPAR𝛄). Activation leads to heterodimerisation with retinoid X receptors (RXR). This complex interacts with DNA via binding to peroxisome proliferator response elements (PPREs) to promote gene transcription for multiple genes and upregulation of proteins involved in glucose and lipid metabolism.

Pharmacokinetics

The following table describes the pharmacokinetic parameters for pioglitazone. Although pioglitazone reaches steady-state concentrations within approximately one week, its glucose-lowering effect develops gradually, with the full therapeutic effect taking considerably longer to become apparent. 

Contraindications

Pioglitazone is contraindicated in the following conditions, further information is available in cautions and adverse effects section:

• Cardiac failure or a history of cardiac failure (NYHA stages I–IV)
• Hepatic impairment 
• Diabetic ketoacidosis 
• Bladder cancer or history of 
• Uninvestigated macroscopic haematuria 

Cautions and Adverse Effects

Heart Failure

Activation of PPARγ in the renal collecting tubules increases sodium reabsorption, contributing to fluid retention and oedema. This can exacerbate or precipitate heart failure and can cause weight gain, typically 1-4kg, which stabilises in 6-12 months. 

Weight gain can also be caused by an increase in adipose tissue with pioglitazone.

Patients should be monitored for signs and symptoms of heart failure, weight gain and oedema, and pioglitazone is contraindicated in heart failure (NYHA stages 1-4) and should be used with caution in those at risk of heart failure (e.g. elderly, previous myocardial infarction).

Osteoporotic Bone Fracture

An increased incidence of bone fractures were observed in clinical trials particularly in women. Epidemiological studies have also suggested an increased fracture risk in men. 

Bladder Cancer

Clinical trials and epidemiological studies have suggested a small increased risk of bladder cancer with pioglitazone, although not all epidemiological studies have demonstrated a statistically significant association. 

Risk factors for bladder cancer include:

• Increasing age
• Smoking
• Previous pelvic radiotherapy
• Exposure to certain occupational or chemotherapy agents, such as cyclophosphamide

Macroscopic haematuria should be investigated prior to starting treatment with pioglitazone, and if any changes to urinary habits should be reported during treatment. The benefits of therapy with pioglitazone still outweigh the risks for patients who respond adequately, however due to increased risk in the elderly, pioglitazone should only be used with caution. 

Hepatic Impairment

Rarely, pioglitazone can cause hepatic impairment, therefore should not be initiated in hepatic impairment and periodic monitoring of liver function tests (including baseline) should be undertaken in any patient receiving treatment with pioglitazone.  

Interactions

Pioglitazone is metabolised by CYP2C8, therefore concomitant administration of CYP2C8 inhibitors such as gemfibrozil and clopidogrel may increase exposure to pioglitazone and inducers such as rifampicin may reduce pioglitazone exposure. 

References

1. Pioglitazone 15 mg Tablets – Summary of Product Characteristics (SmPC) – (emc) | 7407 Accessed 7/8/26
2. Ritter JM, Flower RJ, Henderson G, Loke YK, MacEwan DJ. Rang & Dale’s Pharmacology. 9th ed. London: Elsevier; 2019.
3. Hitchings BSc, M., Lonsdale, D., Burrage, D., Baker, E. (2022). The Top 100 Drugs – E-Book. Netherlands: Elsevier.
4. BNF [online] Accessed 12/8/26
5. BenchChem. Pioglitazone: A Comprehensive Technical Guide to its Regulation of Glucose and Lipid Metabolism. Published April 2026. Accessed 13/8/26. Available from: Pioglitazone: A Comprehensive Technical Guide to its Regulation of Glucose and Lipid Metabolism